Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DSI Renal buys New Smyrna Beach Artificial Kidney Center
On completion of acquisition, the facility, previously owned by KRU Medical, will continue to offer dialysis care and upscale amenities to patients in the New Smyrna Beach area.
On completion of acquisition, the facility, previously owned by KRU Medical, will continue to offer dialysis care and upscale amenities to patients in the New Smyrna Beach area.
Rare disease CDGP, if not treated, in adolescent boys may fail to reach full genetic height potential, experience adverse effects on skeletal proportions and bone mass, and delayed
The approval was based on the positive results of a 12-week multicenter, randomized, vehicle-controlled, double-blind pediatric study, which enrolled 285 acne sufferers aged 9 to 11 years. The
Eylea, which is formulated as an iso-osmotic solution for intravitreal administration, is designed for the treatment of diabetic macular edema (DME) in Russia, China, and other Asian countries.
NX-1207 is in late stage Phase 3 development in the US for the treatment of benign prostatic hyperplasia (BPH), a common condition of older men associated with growth
The study was conducted for a biotech sponsor developing a non-opioid analgesic. Spaulding Clinical Research general manager and senior vice president Daniel Selness said subject safety is the
The program will focus on the discovery of new carbohydrate molecules, which can be used in the therapy of diseases where galectin proteins play a major role, including
Kuiqpick has the additional capability to collect cells from tissues and cultures without affecting their viability, the company said. According to the firm, Kuiqpick can be mounted to
Under the deal both the firms will provide equipment, development, and manufacturing services to the pharmaceutical industry. As part of the agreement, DSM-Chemtrix initially will offer an Industrial
The acceptance of the lixisenatide NDA filing follows the 1 February 2013 European Commission approval of lixisenatide in the European Union (EU), according to Sanofi. The application for